Therapeutic applications of chymase inhibitors in cardiovascular diseases and fibrosis

被引:38
|
作者
Takai, S [1 ]
Jin, D [1 ]
Muramatsu, M [1 ]
Okamoto, Y [1 ]
Miyazaki, M [1 ]
机构
[1] Osaka Med Coll, Dept Pharmacol, Takatsuki, Osaka 5698686, Japan
关键词
angiotensin II; chymase; inhibitor; transforming growth factor-beta;
D O I
10.1016/j.ejphar.2004.08.040
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chymase activates not only angiotensin I to angiotensin 11 but also latent transforming growth factor-beta3-binding protein to transforming growth factor-beta. In dog grafted veins, chymase activity and angiotensin 11 concentration along with vascular proliferation were significantly increased, while they were significantly suppressed by a chymase inhibitor. After balloon injury in dog arteries, chymase activity was significantly increased in the injured artery, and a chymase inhibitor and an angiotensin AT, receptor antagonist were effective in preventing the vascular proliferation, but an angiotensin-converting enzyme inhibitor was ineffective. In fibrotic models, the tissue fibrosis was reduced by chymase inhibitors. In adhesion models, the transforming growth factor-beta concentration and adhesion formation were supressed by chymase inhibitors. Therefore, chymase inhibitors may be useful for preventing cardiovascular diseases and fibrosis via inhibition of angiotensin H formation and transforming growth factor-P activation. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 50 条
  • [41] Therapeutic genome editing in cardiovascular diseases
    Nishiga, Masataka
    Qi, Lei S.
    Wu, Joseph C.
    ADVANCED DRUG DELIVERY REVIEWS, 2021, 168 : 147 - 157
  • [42] The therapeutic potential of sphingolipids for cardiovascular diseases
    Bar, Sapir Ya'ar
    Pintel, Noam
    Abd Alghne, Hesen
    Khattib, Hamdan
    Avni, Dorit
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2023, 10
  • [43] Therapeutic compliance in patients with cardiovascular diseases
    Ramos, MGR
    Hidalgo, JLT
    García, ER
    Rozalén, AA
    Olano, CF
    Verdejo, MAL
    MEDICINA CLINICA, 2002, 118 (10): : 371 - 375
  • [44] VEGF and therapeutic opportunities in cardiovascular diseases
    Schaper, W
    Buschmann, I
    CURRENT OPINION IN BIOTECHNOLOGY, 1999, 10 (06) : 541 - 543
  • [45] Therapeutic Implications of PPARγ in Cardiovascular Diseases
    Hasegawa, Hiroshi
    Takano, Hiroyuki
    Komuro, Issei
    PPAR RESEARCH, 2010, 2010
  • [46] Diagnostic and Therapeutic Nanoparticles in Cardiovascular Diseases
    Tyler, Patrick D.
    Kang, Peter M.
    CURRENT PHARMACEUTICAL DESIGN, 2015, 21 (42) : 6070 - 6080
  • [47] Therapeutic Genome Editing in Cardiovascular Diseases
    German, David M.
    Mitalipov, Shoukhrat
    Mishra, Anusha
    Kaul, Sanjiv
    JACC-BASIC TO TRANSLATIONAL SCIENCE, 2019, 4 (01): : 122 - 131
  • [48] Therapeutic genome editing in cardiovascular diseases
    Wu, Joseph C. (joewu@stanford.edu), 1600, Elsevier B.V. (168):
  • [49] ROCKs as therapeutic targets in cardiovascular diseases
    Rikitake, Yoshiyuki
    Liao, James K.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2005, 3 (03) : 441 - 451
  • [50] Therapeutic Angiogenesis and Regeneration in Cardiovascular Diseases
    Takahashi, Masafumi
    CURRENT PHARMACEUTICAL DESIGN, 2009, 15 (24) : 2759 - 2759